Setmelanotide, an MC4R agonist, is FDA-approved for obesity due to rare genetic syndromes, including BBS, where it has shown significant improvement in appetite regulation and weight outcomes [[6], [7], [8]]. This evidence concerns the gene MC4R and obesity due to melanocortin 4 receptor deficiency.